Effect of repetitive transcranial magnetic stimulation on the kynurenine pathway in stroke patients.
Journal
Neuroreport
ISSN: 1473-558X
Titre abrégé: Neuroreport
Pays: England
ID NLM: 9100935
Informations de publication
Date de publication:
07 06 2020
07 06 2020
Historique:
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
19
8
2021
Statut:
ppublish
Résumé
Repetitive transcranial magnetic stimulation (rTMS) improves depressive symptoms and motor function in stroke patients. While metabolic derangement of the kynurenine pathway has been reported in stroke patients, the effect of rTMS on this pathway remains unknown. This study was performed to investigate the effect of rTMS on serum levels of kynurenine and tryptophan in stroke patients. Sixty-two stroke patients received rTMS in addition to intensive rehabilitation and 33 stroke patients received intensive rehabilitation alone for 14 days. The rTMS involved low-frequency stimulation (at 1 Hz) of the primary motor cortex on the unaffected side of the cerebrum. The depressive state of the patients was evaluated with the Beck Depression Inventory (BDI) before and after treatment. Motor function of the patients was evaluated with Fugl-Meyer Assessment (FMA). Serum levels of kynurenine and tryptophan levels were also measured before and after treatment. The serum tryptophan level decreased in the group receiving rTMS to the right brain and increased in the group receiving rTMS to the left brain. The serum kynurenine/tryptophan ratio was elevated in the group receiving rTMS to the right brain. The BDI indicated improvement of depressive symptoms in the rehabilitation alone group and the group receiving rTMS to the right brain plus rehabilitation. The FMA improved in all groups. The effect of low-frequency rTMS on the kynurenine pathway may differ depending on whether it is applied to the right or left cerebral hemisphere.
Identifiants
pubmed: 32427708
doi: 10.1097/WNR.0000000000001438
pii: 00001756-202006020-00001
doi:
Substances chimiques
Kynurenine
343-65-7
Tryptophan
8DUH1N11BX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
629-636Références
Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. Int J Stroke. 2014; 9:1017–1025
Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990; 47:785–789
Villa RF, Ferrari F, Moretti A. Post-stroke depression: mechanisms and pharmacological treatment. Pharmacol Ther. 2018; 184:131–144
Cuartero MI, de la Parra J, García-Culebras A, Ballesteros I, Lizasoain I, Moro MÁ. The Kynurenine pathway in the acute and chronic phases of cerebral ischemia. Curr Pharm Des. 2016; 22:1060–1073
Koo YS, Kim H, Park JH, Kim MJ, Shin YI, Choi BT, et al. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism contributes to poststroke depression induced in mice by ischemic stroke along with spatial restraint stress. Oxid Med Cell Longev. 2018; 2018:2413841
Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: a meta-analysis adjusting for publication bias. J Psychiatr Res. 2016; 77:42–51
Agudelo LZ, Femenía T, Orhan F, Porsmyr-Palmertz M, Goiny M, Martinez-Redondo V, et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell. 2014; 159:33–45
Martin JL, Barbanoj MJ, Schlaepfer TE, Clos S, Perez V, Kulisevsky J, et al. Transcranial magnetic stimulation for treating depression. Cochrane Database Syst Rev. 2002; 2:CD003493
Lefaucheur JP, André-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clin Neurophysiol. 2014; 125:2150–2206
Niimi M, Hashimoto K, Kakuda W, Miyano S, Momosaki R, Ishima T, Abo M. Role of brain-derived neurotrophic factor in beneficial effects of repetitive transcranial magnetic stimulation for upper limb hemiparesis after stroke. PLoS One. 2016; 11:e0152241
Niimi M, Fujita Y, Ishima T, Hashimoto K, Sasaki N, Hara T, et al. Role of D-serine in the beneficial effects of repetitive transcranial magnetic stimulation in post-stroke patients. Acta Neuropsychiatr. 20191–22
Leblhuber F, Steiner K, Fuchs D. Treatment of patients with geriatric depression with repetitive transcranial magnetic stimulation. J Neural Transm (Vienna). 2019; 126:1105–1110
Kepplinger B, Sedlnitzky-Semler B, Eigner S, Kalina P, Berger P, Baran H. Stroke patients after repetitive transcranial magnetic stimulation (rTMS) – alterations of tryptophan metabolites in the serum. Int J Neurorehabilitation. 2014; 1:128
Ellis C, Grubaugh AL, Egede LE. Factors associated with SF-12 physical and mental health quality of life scores in adults with stroke. J Stroke Cerebrovasc Dis. 2013; 22:309–317
Gu SY, Chang MC. The effects of 10-Hz repetitive transcranial magnetic stimulation on depression in chronic stroke patients. Brain Stimul. 2017; 10:270–274
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189–198
Villardita C. Progressive matrices and intellectual impairment in patients with focal brain damage. Cortex. 1985; 21:627–634
Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. A method for evaluation of physical performance. Scand J Rehabil Med. 1975; 7:13–31
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561–571
Paolucci S, Gandolfo C, Provinciali L, Torta R, Toso V; DESTRO Study Group. The Italian multicenter observational study on post-stroke depression (DESTRO). J Neurol. 2006; 253:556–562
Fujigaki H, Yamamoto Y, Saito K. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: focus on cell type differences. Neuropharmacology. 2017; 112:264–274
Ogyu K, Kubo K, Noda Y, Iwata Y, Tsugawa S, Omura Y, et al. Kynurenine pathway in depression: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2018; 90:16–25
Umehara H, Numata S, Watanabe SY, Hatakeyama Y, Kinoshita M, Tomioka Y, et al. Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder. Sci Rep. 2017; 7:4855
Dahl J, Andreassen OA, Verkerk R, Malt UF, Sandvik L, Brundin L, Ormstad H. Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers. Psychoneuroendocrinology. 2015; 56:12–22
Abo M, Yamauchi H, Suzuki M, Sakuma M, Urashima M. Facilitated beam-walking recovery during acute phase by kynurenic acid treatment in a rat model of photochemically induced thrombosis causing focal cerebral ischemia. Neurosignals. 2006; 15:102–110